Glaxosmithkline | GSK - Ebitda

Aktienkurs
54.44
Täglich Wechseln
-4.68 -7.92%
Monatlich
-8.13%
Jährlich
45.44%
Q2 Prognose
53.52




Ebitda Veränderung Datum
AbbVie USD 3.52B 828M 2025-09
Amgen USD 5.14B 775M 2025-12
AstraZeneca USD 5.23B 272M 2025-09
Aurora Cannabis CAD 18.48M 3.11M 2025-12
Bausch Health Companies USD 986M 74M 2025-09
Bristol-Myers Squibb USD 4.24B 967M 2025-09
Canopy Growth CAD -2.87M 19.49M 2025-12
Corcept Therapeutics USD 4.2M 6.5M 2025-12
Drreddys Laboratories INR 21.59B 1.49B 2025-12
Eli Lilly USD 7.88B 378.1M 2025-09
GlaxoSmithKline GBP 3.36B 179M 2025-09
Glaxosmithkline GBP 4.75B 1.52B 2025-09
J&J USD 7.19B 2.32B 2025-12
Merck USD 8.39B 1.97B 2025-09
Novartis USD 4.77B 1.11B 2025-12
Pacira USD 38.71M 10.65M 2025-12
Perrigo USD 258.8M 37.3M 2025-09
Pfizer USD 6.08B 351M 2025-09
Phibro Animal Health USD 68.1M 6.2M 2025-12
Prestige Brands USD 90.82M 3.99M 2025-12
Roche Holding CHF 12.68B 2.36B 2024-06
Sanofi EUR 3.31B 3.65B 2026-03
Supernus Pharmaceuticals USD 48.5M 6.6M 2025-12
Takeda JPY 448.13B 173.98B 2025-12
Teva Pharmaceutical Industries USD 1.64B 243M 2025-12
Zoetis USD 1.04B 87M 2025-09